Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Gastrointestinal 4Thoracic 2Genitourinary 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 14Lung Neoplasms 9Stomach Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Colonic Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Mesothelioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinocerebellar Degenerations 1Somatostatinoma 1Sezary Syndrome 1Pseudomyxoma Peritonei 1

Interventions

pembrolizumab 30Carboplatin 13Trastuzumab 8Paclitaxel 7Nivolumab 7Cisplatin 6Ipilimumab 5Cetuximab 5Bevacizumab 5Taxes 4Pemetrexed 4Specimen Handling 3Irinotecan 3Docetaxel 3Cyclophosphamide 3Biopsy 3tisotumab vedotin 2temsirolimus 2spartalizumab 2sargramostim 2pertuzumab 2lenvatinib 2fludarabine 2epacadostat 2enzalutamide 2aldesleukin 2X-Rays 2Ritonavir 2Psychiatric Rehabilitation 2Oxaliplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Leucovorin × Thoracic × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡